Literature DB >> 20016212

Immunolocalization and mRNA expression of bone morphogenetic protein-6 in human clear cell renal carcinoma.

Nikolina Basic-Jukic1, Margareta Radic-Antolic, Tvrtko Hudolin, Marijana Coric, Renata Zadro, Josip Pasini, Zeljko Kastelan, Petar Kes.   

Abstract

Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-beta superfamily of proteins. Dysregulation of BMP signaling has been suggested in the carcinogenesis of different organs. We determined BMP-6 mRNA and protein expression in localized human clear cell renal carcinoma (CCRC), obtained from 20 patients who underwent nephrectomy, by the real-time polymerase chain reaction and immunohistochemistry. 15/20 patients exhibited higher BMP-6 mRNA expression in malignant than in healthy renal tissue relative to the PBGD expression (p < 0.05). Immunostaining intensity for BMP-6 in healthy renal tissue ranged from 0 to 2 (average 0.9), as well as in renal clear cell carcinoma (average 1.1). Seven of 20 (35%) healthy tissue samples failed to stain with BMP-6 antibody, compared to 2/20 (10%) tumor samples (p < 0.05). BMP-6 immunostaining was positive in 18/20 CCRC samples. Staining was localized in the cytoplasm and/or membrane of malignant cells. Malignant tissue had significantly higher BMP-6 mRNA expression than healthy tissue. There was no significant correlation between BMP-6 mRNA and protein expression with disease presentation, disease progression and patients' characteristics. Long-term follow-up of our patients is needed to determine the possible role of increased expression of BMP-6 in CCRC. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20016212     DOI: 10.1159/000266479

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  5 in total

1.  Combinatorial use of bone morphogenetic protein 6, noggin and SOST significantly predicts cancer progression.

Authors:  Hiu-Fung Yuen; Cian M McCrudden; Claire Grills; Shu-Dong Zhang; Yu-Han Huang; Ka-Kui Chan; Yuen-Piu Chan; Michelle Lok-Yee Wong; Simon Law; Gopesh Srivastava; Dean A Fennell; Glenn Dickson; Mohamed El-Tanani; Kwok-Wah Chan
Journal:  Cancer Sci       Date:  2012-04-03       Impact factor: 6.716

2.  Expression of bone morphogenetic proteins 4, 6 and 7 is downregulated in kidney allografts with interstitial fibrosis and tubular atrophy.

Authors:  Vesna Furic-Cunko; Petar Kes; Marijana Coric; Tvrtko Hudolin; Zeljko Kastelan; Nikolina Basic-Jukic
Journal:  Int Urol Nephrol       Date:  2015-05-12       Impact factor: 2.370

3.  Bone morphogenetic protein signaling: implications in urology.

Authors:  Jeongyun Jeong; Dong Il Kang; Geun Taek Lee; Isaac Yi Kim
Journal:  Korean J Urol       Date:  2010-08-18

4.  In vitro and in vivo studies on the effects of bone morphogenetic protein-7 on human kidney and lung tumor cells.

Authors:  Lee-Chuan C Yeh
Journal:  Int J Biomed Sci       Date:  2010-09

5.  Bone morphogenic proteins-2, -4, -6 and 7 in non-muscle invasive bladder cancer.

Authors:  Tvrtko Hudolin; Zeljko Kastelan; Ahmad El-Saleh; Mirko Bakula; Marijana Coric; Petar Kes; Davor Tomas; Nikolina Basic-Jukic
Journal:  Oncol Lett       Date:  2019-12-13       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.